Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 98
Filter
1.
Mult Scler ; 24(13): 1753-1759, 2018 11.
Article in English | MEDLINE | ID: mdl-28920766

ABSTRACT

BACKGROUND: In a minority of patients with neuromyelitis optica spectrum disorder (NMOSD) and aquaporin-4 antibodies (AQP4-IgG), the disease has a paraneoplastic origin. It is unknown whether these patients have distinctive clinical features. OBJECTIVE: To report the clinical features of a series of patients with paraneoplastic NMOSD and AQP4-IgG and to review previously reported cases. METHODS: Retrospective analysis of clinical records of 156 patients with NMOSD and AQP4-IgG and review of previously reported patients with paraneoplastic NMOSD and AQP4-IgG. Paraneoplastic patients were defined as those with cancer identified within 2 years of the diagnosis of NMOSD. RESULTS: Five (3.2%) of 156 patients had paraneoplastic NMOSD, and 12 previously reported patients were identified. The most common tumors were adenocarcinoma of the lung (five patients) and breast (five). Compared with the 151 non-paraneoplastic NMOSD patients, the 17 (5 current cases and 12 previously reported) were older at symptom onset (median age = 55 (range: 17-87) vs 40 (range: 10-77) years; p = 0.006), more frequently male (29.4% vs 6.6%; p = 0.009), and presented with severe nausea and vomiting (41.2% vs 6.6%; p < 0.001). The frequency of longitudinal extensive transverse myelitis (LETM) as heralding symptom was similar in both groups, but patients with paraneoplastic NMOSD were older than those with non-paraneoplastic NMOSD (median age: 63 (range: 48-73) vs 43 (range: 14-74) years; p = 0.001). CONCLUSION: Patients, predominantly male, with NMOSD and AQP4-IgG should be investigated for an underlying cancer if they present with nausea and vomiting, or LETM after 45 years of age.


Subject(s)
Adenocarcinoma/drug therapy , Aquaporin 4/immunology , Autoantibodies/blood , Neuromyelitis Optica/drug therapy , Adenocarcinoma/immunology , Aged , Female , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Myelitis, Transverse/immunology , Neuromyelitis Optica/immunology , Retrospective Studies
3.
Oncol Lett ; 13(6): 4093-4100, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28599411

ABSTRACT

The present observational, multicenter, retrospective study investigated the efficacy and tolerability of lacosamide in controlling secondary epileptic seizures in patients with brain tumors in Spain. Data from the medical records of patients ≥18 years of age with brain tumors, who had received at least one dose of lacosamide for seizure management between July 2013 and November 2013, were collected. The primary and secondary objectives of the present study were to assess the effectiveness and tolerability of lacosamide. Data from 39 patients (mean age, 54.1 years; 66.7% male) were collected, where the two main reasons for initiation of lacosamide treatment were the lack of efficacy of other antiepileptic drugs (in 76.9% of patients) and the presence of adverse events (12.8%) associated with other antiepileptic drugs. At the initiation of treatment, patients received a mean lacosamide dose of 138.5±68.3 mg/day. At 6 months, lacosamide had significantly reduced the mean number of seizures from 26.4 (standard deviation [SD], 50.4) seizures for the 6 months prior to lacosamide initiation to a mean of 9.4 (SD, 22.8) seizures during the 6 months subsequent to lacosamide initiation; P<0.001. Lacosamide was generally well tolerated; of the 25 patients who had complete safety data available at a 6-month follow-up, 3 patients (12%) reported an adverse event, including dizziness, asthenia, instability and irritability. The present retrospective analysis suggested that lacosamide is an effective and well-tolerated treatment in patients experiencing seizures due to brain tumors. Additional prospective studies with a larger patient population and randomized trial design are warranted.

4.
Surg Neurol Int ; 3: 88, 2012.
Article in English | MEDLINE | ID: mdl-23050202

ABSTRACT

BACKGROUND: Nocardial brain abscesses are a rare central nervous system infection with high morbidity and mortality. Infection is acquired through inhalation or direct innoculation and then spreads hematogenously. They are usually associated with immunocompromised patients but may appear in otherwise healthy individuals. Treatment is based on surgical aspiration and antibiotics for several months. CASE DESCRIPTION: We present four cases of nocardial brain abscesses treated at our institution and review the literature regarding these lesions. Ages ranged from 22 to 71 years. One patient was a healthy individual without any predisposing condition. Patients were treated with surgical evacuation and long term parenteral antibiotics. Two patients made a full recovery; one patient died and one recovered with significant morbidity. In one case malignancy was suspected, probably delaying diagnosis. CONCLUSIONS: Nocardial brain abscesses are a rare condition that needs to be considered in the differential diagnosis of brain lesions. They are not necessarily associated with predisposing factors such as immunosupresion. Treatment must be started as soon as possible with surgical evacuation and long term parenteral antibiotics in order to avoid significant morbidity.

5.
Int J Radiat Oncol Biol Phys ; 84(5): 1151-8, 2012 Dec 01.
Article in English | MEDLINE | ID: mdl-22516806

ABSTRACT

PURPOSE: Management of locally advanced rectal cancer (RC) consists of neoadjuvant chemoradiotherapy (CRT) with fluoropyrimidines, followed by total mesorectal excision. We sought to evaluate the expression of selected genes, some of which were derived from a previous undirected SAGE (serial analysis of gene expression)-based approach, before and after CRT, to identify mechanisms of resistance. METHODS: This retrospective cohort study included 129 consecutive patients. Quantitative polymerase chain reaction of 53 candidate genes was performed on the biopsy specimen before treatment and on the surgical specimen after CRT. A paired-samples t test was performed to determine genes that were significantly changed after CRT. The result was correlated with patients' disease-free survival. RESULTS: Twenty-two genes were significantly upregulated, and two were significantly downregulated. Several of the upregulated genes have roles in cell cycle control; these include CCNB1IP1, RCC1, EEF2, CDKN1, TFF3, and BCL2. The upregulation of TFF3 was associated with worse disease-free survival on multivariate analyses (hazard ratio, 2.64; P=.027). Patients whose surgical specimens immunohistochemically showed secretion of TFF3 into the lumen of the tumoral microglands had a higher risk of relapse (hazard ratio, 2.51; P=.014). In vitro experiments showed that DLD-1 cells stably transfected with TFF3 were significantly less sensitive to 5-fluorouracil and showed upregulation of genes involved in the transcriptional machinery and in resistance to apoptosis. CONCLUSION: Upregulation of TFF3 after CRT for RC is associated with a higher risk of relapse. The physiological role of TFF3 in restoring the mucosa during CRT could be interfering with treatment efficacy. Our results could reveal not only a novel RC prognostic marker but also a therapeutic target.


Subject(s)
Adenocarcinoma/metabolism , Chemoradiotherapy, Adjuvant , Neoplasm Proteins/metabolism , Neoplasm Recurrence, Local , Peptides/metabolism , Rectal Neoplasms/metabolism , Rectal Neoplasms/therapy , Adenocarcinoma/genetics , Adult , Aged , Aged, 80 and over , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cell Line, Tumor , Chemoradiotherapy, Adjuvant/methods , Disease-Free Survival , Drug Resistance, Neoplasm/genetics , Female , Gene Expression Profiling/methods , Humans , Male , Middle Aged , Multivariate Analysis , Neoplasm Proteins/genetics , Peptides/genetics , Polymerase Chain Reaction , Prognosis , Protein Array Analysis/methods , Rectal Neoplasms/genetics , Retrospective Studies , Transfection/methods , Trefoil Factor-3 , Up-Regulation , Young Adult
6.
Alzheimer Dis Assoc Disord ; 26(1): 91-5, 2012.
Article in English | MEDLINE | ID: mdl-22354140

ABSTRACT

Late-onset Alzheimer disease (LOAD) is a complex genetic disorder. Although genes involved in early-onset forms were discovered more than a decade ago, LOAD research has only been able to point out small effect loci, with the exception of APOE. We mapped the gene predisposing to LOAD in an extended inbred family coming from a genetically isolated region (24 sampled individuals, 12 of whom are affected), completing a genome-wide screen with an Affymetrix10 K single nucleotide polymorphism microarray. Genotyping results were evaluated under model-dependent (dominant and recessive) and model-free analysis. We obtained a maximum nonparametric linkage score of 3.24 (P=0.00006) on chromosome 8p22-p21.2. The same genomic position also yielded the highest multipoint heterogeneity LOD (HLOD) under a recessive model (HLOD=3.04). When we compared the results of the model-dependent analysis, a higher score was obtained in the recessive model (3.04) than in the dominant model (1.0). This is a new locus identified in LOAD, in chromosome 8p22-p21.2 and encompassing several candidate genes, among them CLU and PPP3CC that were excluded by sequencing. The finding of a recessive model of inheritance, consistent with the assumption of inbreeding as a morbidity factor in this population, supports the notion of a role of recessive genes in LOAD.


Subject(s)
Alzheimer Disease/genetics , Chromosomes, Human, Pair 8 , Genes, Recessive , Genetic Linkage , Age of Onset , Alzheimer Disease/epidemiology , Apolipoproteins E/genetics , Chromosome Mapping , Female , Genetic Loci , Genetic Predisposition to Disease/genetics , Genome , Genome-Wide Association Study , Genotype , Humans , Lod Score , Male , Pedigree , Polymorphism, Single Nucleotide/genetics
7.
Urol Oncol ; 30(4): 356-61, 2012.
Article in English | MEDLINE | ID: mdl-20207176

ABSTRACT

Renal cell carcinoma therapy has changed in a very significant way in the last few years. Up to 5 new agents have been developed, improving the results previously achieved with cytokine therapy. Bevacizumab, sorafenib, sunitinib, temsirolimus, and everolimus are now part of the therapeutic arsenal for this illness. Particularly, this has been the first tumoral type in which inhibition of mammalian target of rapamycin (mTOR) has proved its efficacy in phase III trials, either as first-line therapy for poor prognosis patients (temsirolimus, CCI-779) or as second-line therapy after failure of tyrosine-kinase inhibitors (everolimus, RAD001). In this paper, we review the basis for mTOR inhibition in RCC, and discuss the results of the trials involving temsirolimus and everolimus for the treatment of this disease.


Subject(s)
Carcinoma, Renal Cell/enzymology , Kidney Neoplasms/enzymology , Signal Transduction , TOR Serine-Threonine Kinases/metabolism , Carcinoma, Renal Cell/drug therapy , Clinical Trials, Phase III as Topic , Everolimus , Humans , Kidney Neoplasms/drug therapy , Protein Kinase Inhibitors/therapeutic use , Sirolimus/analogs & derivatives , Sirolimus/therapeutic use , TOR Serine-Threonine Kinases/antagonists & inhibitors , Treatment Outcome
8.
J Gastrointest Cancer ; 43(2): 181-9, 2012 Jun.
Article in English | MEDLINE | ID: mdl-21360269

ABSTRACT

INTRODUCTION: TNM and histological subtype are the most important prognostic criteria in gastric cancer. In this study, we have tried to identify an immunohistochemical protein profile involved in gastric recurrence after a radical surgery. MATERIALS AND METHODS: In this paper, protein panels involved in gastric carcinogenesis and progression was analyzed by immunohistochemistry expression: p53, Ki-67, Bcl-2, COX-2, c-erb-B2, EPO-R, E-cadherin, and ß-catenin in 44 gastrectomy samples coming from gastrectomy pieces of patients diagnosed and operated on adenocarcinoma of the stomach followed by adjuvant treatment based on MacDonald chemoradiation regimen. An immunostaining profile that could predict the relapse after the end of adjuvant treatment was tried to find. These results have shown that the expression of the adverse prognostic protein profile based on positive p53 immunohistochemical expression and non-conserved E-cadherin/B-catenin staining is associated with tumor recurrence and a poor disease-free survival in operated gastric cancer patients with curative intent followed by adjuvant chemoradiation according to MacDonald's regimen. A protein profile based on immunohistochemical expression of p53 and E-cadherin-B-catenin that has a significant correlation to disease-free survival was identified in gastric cancer samples.


Subject(s)
Adenocarcinoma/metabolism , Biomarkers, Tumor/analysis , Neoplasm Recurrence, Local/metabolism , Stomach Neoplasms/metabolism , Adenocarcinoma/pathology , Adenocarcinoma/therapy , Adult , Aged , Cadherins/analysis , Cadherins/biosynthesis , Chemoradiotherapy, Adjuvant , Disease Progression , Female , Humans , Immunohistochemistry , Kaplan-Meier Estimate , Male , Middle Aged , Neoplasm Grading , Neoplasm Recurrence, Local/epidemiology , Neoplasm Recurrence, Local/pathology , Neoplasm Staging , Prognosis , Retrospective Studies , Stomach Neoplasms/pathology , Stomach Neoplasms/therapy , Tumor Suppressor Protein p53/analysis , Tumor Suppressor Protein p53/biosynthesis , beta Catenin/analysis , beta Catenin/biosynthesis
9.
J Natl Cancer Inst ; 103(21): 1613-20, 2011 Nov 02.
Article in English | MEDLINE | ID: mdl-21972226

ABSTRACT

BACKGROUND: Determining life expectancy in terminally ill cancer patients is a difficult task. We aimed to develop and validate a nomogram to predict the length of survival in patients with terminal disease. METHODS: From February 1, 2003, to December 31, 2005, 406 consecutive terminally ill patients were entered into the study. We analyzed 38 features prognostic of life expectancy among terminally ill patients by multivariable Cox regression and identified the most accurate and parsimonious model by backward variable elimination according to the Akaike information criterion. Five clinical and laboratory variables were built into a nomogram to estimate the probability of patient survival at 15, 30, and 60 days. We validated and calibrated the nomogram with an external validation cohort of 474 patients who were treated from June 1, 2006, through December 31, 2007. RESULTS: The median overall survival was 29.1 days for the training set and 18.3 days for the validation set. Eastern Cooperative Oncology Group performance status, lactate dehydrogenase levels, lymphocyte levels, albumin levels, and time from initial diagnosis to diagnosis of terminal disease were retained in the multivariable Cox proportional hazards model as independent prognostic factors of survival and formed the basis of the nomogram. The nomogram had high predictive performance, with a bootstrapped corrected concordance index of 0.70, and it showed good calibration. External independent validation revealed 68% predictive accuracy. CONCLUSIONS: We developed a highly accurate tool that uses basic clinical and analytical information to predict the probability of survival at 15, 30, and 60 days in terminally ill cancer patients. This tool can help physicians making decisions on clinical care at the end of life.


Subject(s)
Life Expectancy , Neoplasms , Nomograms , Terminally Ill , Activities of Daily Living , Adolescent , Adult , Aged , Aged, 80 and over , Biomarkers/blood , Cognition Disorders/epidemiology , Cognition Disorders/etiology , Disease Progression , Female , Humans , Kaplan-Meier Estimate , Lymphocyte Count , Male , Middle Aged , Multivariate Analysis , Neoplasm Staging , Neoplasms/pathology , Neoplasms/physiopathology , Palliative Care , Predictive Value of Tests , Prognosis , Proportional Hazards Models , Reproducibility of Results , Research Design , Risk Assessment , Risk Factors , Spain/epidemiology , Time Factors , Weight Loss
10.
Clin Cancer Res ; 17(12): 4145-54, 2011 Jun 15.
Article in English | MEDLINE | ID: mdl-21467161

ABSTRACT

PURPOSE: Preoperative chemoradiotherapy (CRT) is the treatment of choice for rectal cancer (RC), but half of the patients do not respond, suffer unnecessary toxicities, and surgery delays. We aimed to develop a model that could predict a clinically meaningful response to CRT by using formalin-fixed paraffin-embedded (FFPE) biopsies. EXPERIMENTAL DESIGN: We first carried out an exploratory screening of candidate genes by using SAGE technology to evaluate dynamic changes in the RC transcriptome in selected refractory patients before and after CRT. Next, 53 genes (24 from SAGE and 29 from the literature) were analyzed by qPCR arrays in FFPE initial biopsies from 94 stage II/III RC patients who were preoperatively treated with CRT. Tumor response was defined by using Dworak's tumor regression grade (2-3-4 vs. 0-1). Multivariate Cox methods and stepwise algorithms were applied to generate an optimized predictor of response and outcome. RESULTS: In the training cohort (57 patients), a 13-gene signature predicted tumor response with 86% accuracy, 87% sensitivity, and 82% specificity. In a testing cohort (37 patients), the model correctly classified 6 of 7 nonresponders, with an overall accuracy of 76%. A signature-based score identified patients with a higher risk of relapse in univariate (3-year disease-free survival 64% vs. 90%, P = 0.001) and multivariate analysis (HR = 4.35 95% CI: 1.2-15.75, P = 0.02), in which it remained the only statistically significant prognostic factor. CONCLUSIONS: A basal 13-gene signature efficiently predicted CRT response and outcome. Multicentric validation by the GEMCAD collaborative group is currently ongoing. If confirmed, the predictor could be used to improve patient selection in RC studies.


Subject(s)
Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Rectal Neoplasms/diagnosis , Rectal Neoplasms/therapy , Biomarkers, Tumor/metabolism , Humans , Neoadjuvant Therapy , Prognosis , Rectal Neoplasms/genetics , Rectal Neoplasms/mortality , Survival Analysis , Treatment Outcome
11.
J Clin Oncol ; 29(9): 1159-67, 2011 Mar 20.
Article in English | MEDLINE | ID: mdl-21343566

ABSTRACT

PURPOSE: The purpose of this study was to identify factors associated with at-home death among patients with advanced cancer and create a decision-making model for discharging patients from an acute-care hospital. PATIENTS AND METHODS: We conducted an observational cohort study to identify the association between place of death and the clinical and demographic characteristics of patients with advanced cancer who received care from a palliative home care team (PHCT) and of their primary caregivers. We used logistic regression analysis to identify the predictors of at-home death. RESULTS: We identified 380 patients who met the study inclusion criteria; of these, 245 patients (64%) died at home, 72 (19%) died in an acute-care hospital, 60 (16%) died in a palliative care unit, and three (1%) died in a nursing home. Median follow-up was 48 days. We included the 16 variables that were significant in univariate analysis in our decision-making model. Five variables predictive of at-home death were retained in the multivariate analysis: caregiver's preferred place of death, patients' preferred place of death, caregiver's perceived social support, number of hospital admission days, and number of PHCT visits. A subsequent reduced model including only those variables that were known at the time of discharge (caregivers' preferred place of death, patients' preferred place of death, and caregivers' perceived social support) had a sensitivity of 96% and a specificity of 81% in predicting place of death. CONCLUSION: Asking a few simple patient- and family-centered questions may help to inform the decision regarding the best place for end-of-life care and death.


Subject(s)
Decision Making , Home Care Services/statistics & numerical data , Neoplasms/mortality , Neoplasms/psychology , Palliative Care , Patient Discharge/standards , Terminal Care/organization & administration , Adolescent , Adult , Aged , Aged, 80 and over , Cohort Studies , Female , Hospitalization , Humans , Male , Middle Aged , Neoplasms/therapy , Prospective Studies , Survival Rate , Treatment Outcome , Young Adult
12.
J Neurol Neurosurg Psychiatry ; 82(12): 1399-401, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21148607

ABSTRACT

BACKGROUND: Glycine receptor antibodies (GlyR-ab) were reported in a patient with progressive encephalomyelitis with rigidity and myoclonus (PERM). METHODS: Three additional patients were clinically described. GlyR-ab was detected with a cell-based assay of HEK293 cells transfected with the α1 subunit of the GyR. RESULTS: A 33-year-old woman presented with diplopia, dysphagia and gait ataxia that improved in 5 weeks. Then, she developed a typical stiff-person syndrome (SPS) that resolved with corticosteroids, but relapsed 17 months later with a stiff limb syndrome. After treatment with intravenous immunoglobulins (IVIG), she has been asymptomatic for 8 years. A 60-year-old man developed, dysphagia, diplopia, left facial palsy and right trigeminal hypoaesthesia in a few days, followed by muscular rigidity, corticospinal signs, myoclonic jerks and severe dysautonomia. He developed seizures and suffered a cardiac arrest that left him in a persistent vegetative state. A 48-year-old man presented with leg rigidity and frequent spells of trismus, muscle spasms followed by opisthotonus and diaphoresis. The symptoms were antedated by pruritus of the left scapulae, right arm and T11-T12 dermatome. At the same time he became progressively more aggressive with emotional irritability. He also developed dysgeusia (metallic taste) and severe concurrent behavioural changes and diurnal hypersomnia. Only the rigidity and the spasms improved after therapy. CONCLUSIONS: The clinical picture associated with GlyR-ab is wider than the classical view of PERM. GlyR-ab should be examined in patients with core symptoms of muscle rigidity and spasms atypical for SPS.


Subject(s)
Encephalomyelitis/immunology , Muscle Rigidity/immunology , Receptors, Glycine/immunology , Adult , Antibodies/blood , Encephalomyelitis/complications , Female , HEK293 Cells , Humans , Male , Middle Aged , Muscle Rigidity/complications , Myoclonus/complications , Myoclonus/immunology
13.
BMC Cancer ; 10: 336, 2010 Jun 28.
Article in English | MEDLINE | ID: mdl-20584321

ABSTRACT

BACKGROUND: Gene expression profiling may improve prognostic accuracy in patients with early breast cancer. Our objective was to demonstrate that it is possible to develop a simple molecular signature to predict distant relapse. METHODS: We included 153 patients with stage I-II hormonal receptor-positive breast cancer. RNA was isolated from formalin-fixed paraffin-embedded samples and qRT-PCR amplification of 83 genes was performed with gene expression assays. The genes we analyzed were those included in the 70-Gene Signature, the Recurrence Score and the Two-Gene Index. The association among gene expression, clinical variables and distant metastasis-free survival was analyzed using Cox regression models. RESULTS: An 8-gene prognostic score was defined. Distant metastasis-free survival at 5 years was 97% for patients defined as low-risk by the prognostic score versus 60% for patients defined as high-risk. The 8-gene score remained a significant factor in multivariate analysis and its performance was similar to that of two validated gene profiles: the 70-Gene Signature and the Recurrence Score. The validity of the signature was verified in independent cohorts obtained from the GEO database. CONCLUSIONS: This study identifies a simple gene expression score that complements histopathological prognostic factors in breast cancer, and can be determined in paraffin-embedded samples.


Subject(s)
Breast Neoplasms/genetics , Gene Expression Profiling/methods , Gene Expression Regulation, Neoplastic , Genetic Testing/methods , Polymerase Chain Reaction , Breast Neoplasms/diagnosis , Breast Neoplasms/mortality , Breast Neoplasms/secondary , Breast Neoplasms/therapy , Databases, Genetic , Female , Genetic Predisposition to Disease , Humans , Kaplan-Meier Estimate , Middle Aged , Neoplasm Staging , Paraffin Embedding , Predictive Value of Tests , Prognosis , Proportional Hazards Models , Reproducibility of Results , Retrospective Studies , Risk Assessment , Risk Factors , Time Factors
14.
Biotechniques ; 48(5): 389-97, 2010 May.
Article in English | MEDLINE | ID: mdl-20569212

ABSTRACT

Recent reports demonstrate the feasibility of quantifying gene expression by using RNA isolated from blocks of formalin-fixed, paraffin-embedded (FFPE) tumor tissue. The development of molecular tests for clinical use based on archival materials would be of great utility in the search for and validation of important genes or gene expression profiles. In this study, we compared the performance of different normalization strategies in the correlation of quantitative data between fresh frozen (FF) and FFPE samples and analyzed the parameters that characterize such correlation for each gene. Total RNA extracted from FFPE samples presented a shift in raw cycle threshold (Cq) values that can be explained by its extensive degradation. Proper normalization can compensate for the effects of RNA degradation in gene expression measurements. We show that correlation between normalized expression values is better for moderately to highly expressed genes whose expression varies significantly between samples. Nevertheless, some genes had no correlation. These genes should not be included in molecular tests for clinical use based on FFPE samples. Our results could serve as a guide when developing clinical diagnostic tests based on RT-qPCR analyses of FFPE tissues in the coming era of treatment decision-making based on gene expression profiling.


Subject(s)
Breast Neoplasms/genetics , Formaldehyde/chemistry , Frozen Sections , Gene Expression Profiling/methods , Paraffin Embedding , Reverse Transcriptase Polymerase Chain Reaction/methods , Tissue Fixation , Biological Assay , Breast Neoplasms/pathology , Female , Fixatives/chemistry , Gene Expression Regulation, Neoplastic , Genes, Neoplasm/genetics , Humans , Reference Standards
15.
Support Care Cancer ; 18(9): 1231-4, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20508952

ABSTRACT

PURPOSE: The impact that palliative care services have had on admission to oncology services has not been well-defined. This retrospective study was undertaken in the oncology service of a general hospital where there is also a palliative care service. METHODS: The medical records of 397 patients (542 events) admitted during a period of 6 months at a single centre were reviewed. RESULTS: The main final diagnoses were tumour progression, infection and chemotherapy administration. Seventeen percent of patients died during hospitalisation. The decision to withdraw active treatment was taken during this time in 11% of patients. CONCLUSION: Key therapeutic decisions are commonly made during hospitalisation events of patients with cancer. Our results suggest that oncologists still take care of patients at the end of life, although this may highly depend on models of health care and admission criteria.


Subject(s)
Hospitalization , Neoplasms/nursing , Oncology Service, Hospital , Palliative Care , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Medical Audit , Middle Aged , Young Adult
16.
J Cancer Res Clin Oncol ; 136(12): 1915-20, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20213094

ABSTRACT

Bladder cancer, in its advanced stage, has very few therapeutic strategies with proven efficacy. Platinum-combination chemotherapy can be considered a standard for first-line therapy, but after progression there is no standard therapy, and the prognosis is very poor. The development of targeted therapies in the last few years has significantly changed the prognosis of a wide variety of tumors. In bladder cancer, there is no targeted therapy currently approved for its use in advanced disease. There is evidence that Her-2 amplification and/or overexpression is seen in bladder cancer, and may influence prognosis. Anti-Her-2 drugs, such as trastuzumab or lapatinib, are under investigation in urothelial neoplasms, but there is no phase III trial that has evaluated their use in bladder cancer. We review the published evidence about Her-2 determination, its influence on bladder carcinoma prognosis, the clinical development of anti-Her-2-targeted therapies, and the possible future research directions involving this pathway in bladder cancer.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Quinazolines/therapeutic use , Receptor, ErbB-2/antagonists & inhibitors , Urinary Bladder Neoplasms/drug therapy , Antibodies, Monoclonal, Humanized , Antineoplastic Agents/therapeutic use , Gene Expression Regulation, Neoplastic , Humans , Lapatinib , Models, Biological , Prognosis , Receptor, ErbB-2/genetics , Receptor, ErbB-2/metabolism , Signal Transduction/drug effects , Trastuzumab , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/metabolism
17.
J Alzheimers Dis ; 19(3): 873-84, 2010.
Article in English | MEDLINE | ID: mdl-20157243

ABSTRACT

We describe the clinical phenotype of nine kindred with presenile Alzheimer's disease (AD) caused by different presenilin 1 (PS1) point mutations, and compare them with reported families with mutations in the same codons. Mutations were in exon 4 (Phe105Val), exon 5 (Pro117Arg, Glu120Gly), exon 6 (His163Arg), exon 7 (Leu226Phe), exon 8 (Val261Leu, Val272Ala, Leu282Arg), and exon 12 (Ile439Ser). Three of these amino acid changes (Phe105Val, Glu120Gly, and Ile439Ser) had not been previously reported. Distinct clinical features, including age of onset, symptoms and signs associated with the cortical-type dementia and aggressiveness of the disease, characterized the different mutations and were quite homogeneous across family members. Age of onset fell within a consistent range: some mutations caused the disease in the thirties (P117R, L226F, V272A), other in the forties (E120G, H163R, V261L, L282R), and other in the fifties (F105V, I439S). Associated features also segregated with specific mutations: early epileptic activity (E120G), spastic paraparesis (V261L), subcortical dementia and parkinsonism (V272A), early language impairment, frontal signs, and myoclonus (L226F), and late myoclonus and seizures (H163R, L282R). Neurological deterioration was particularly aggressive in PS1 mutations with earlier age of onset such as P117R, L226F, and E120G. With few exceptions, a similar clinical phenotype was found in families reported to have either the same mutation or different amino acid changes in the same codons. This series points to a strong influence of the specific genetic defect in the development of the clinical phenotype.


Subject(s)
Alzheimer Disease/genetics , Point Mutation/genetics , Presenilin-1/genetics , Adult , Aged , Alzheimer Disease/diagnosis , Electroencephalography , Exons/genetics , Female , Humans , Male , Middle Aged , Pedigree , Phenotype , Prospective Studies
19.
PLoS One ; 4(12): e8199, 2009 Dec 18.
Article in English | MEDLINE | ID: mdl-20020061

ABSTRACT

BACKGROUND: KRAS mutations in colorectal cancer primary tumors predict resistance to anti-Epidermal Growth Factor Receptor (EGFR) monoclonal antibody therapy in patients with metastatic colorectal cancer, and thus represent a true indicator of EGFR pathway activation status. METHODOLOGY/PRINCIPAL FINDINGS: KRAS mutations were retrospectively studied using polymerase chain reactions and subsequent sequencing of codons 12 and 13 (exon 2) in 110 patients with metastatic colorectal tumors. These studies were performed using tissue samples from both the primary tumor and their related metastases (93 liver, 84%; 17 lung, 16%). All patients received adjuvant 5-Fluorouracil-based polychemotherapy after resection of metastases. None received anti-EGFR therapy. Mutations in KRAS were observed in 37 (34%) of primary tumors and in 40 (36%) of related metastases, yielding a 94% level of concordance (kappa index 0.86). Patients with primary tumors possessing KRAS mutations had a shorter disease-free survival period after metastasis resection (12.0 vs 18.0 months; P = 0.035) than those who did not. A higher percentage of KRAS mutations was detected in primary tumors of patiens with lung metastases than in patients with liver metastases (59% vs 32%; p = 0.054). To further evaluate this finding we analyzed 120 additional patients with unresectable metastatic colorectal cancer who previously had their primary tumors evaluated for KRAS mutational status for clinical purposes. Separately, the analysis of these 120 patients showed a tendency towards a higher degree of KRAS mutations in primary tumors of patients with lung metastases, although it did not reach statistical significance. Taken together the group of 230 patients showed that KRAS was mutated significantly more often in the primary tumors of patients with lung metastases (57% vs 35%; P = 0.006). CONCLUSIONS/SIGNIFICANCE: Our results suggest a role for KRAS mutations in the propensity of primary colorectal tumors to metastasize to the lung.


Subject(s)
Colorectal Neoplasms/genetics , Colorectal Neoplasms/pathology , Lung Neoplasms/diagnosis , Lung Neoplasms/secondary , Mutation/genetics , Proto-Oncogene Proteins/genetics , ras Proteins/genetics , Adult , Aged , Aged, 80 and over , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Multivariate Analysis , Proto-Oncogene Proteins p21(ras)
20.
Clin Transl Oncol ; 11(11): 727-36, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19917536

ABSTRACT

Treatment of anaemia is a very important aspect in the management of cancer patients. In order to carry out a consensus process about the use of erythropoietic stimulating agents (ESAs) in cancer patients, the Spanish Society of Medical Oncology (SEOM) elaborated a working group which coordinated a panel of medical oncology specialists. This working group has reviewed the main issues about the use of ESAs. In addition a consensus meeting was held in Madrid on 25 April 2007. The following conclusions were made: Since ESA treatment increases the haemoglobin (Hb) level and decreases the red blood cell (RBC) transfusion requirements, ESAs should be used within the approved indications in patients undergoing chemotherapy treatment, beginning at a Hb level below 11 g/dl and maintaining it around 12 g/dl, with iron supplements if necessary. Neither increasing the ESA dose in nonresponders nor the use of ESAs in the treatment of chronic cancer-related anaemia is recommended.


Subject(s)
Anemia/complications , Anemia/drug therapy , Hematinics/therapeutic use , Medical Oncology/methods , Neoplasms/complications , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Blood Transfusion , Chronic Disease/therapy , Clinical Trials as Topic , Erythrocytes/metabolism , Hemoglobins/metabolism , Humans , Iron/metabolism , Practice Guidelines as Topic , Spain
SELECTION OF CITATIONS
SEARCH DETAIL
...